{"id":"hip2101","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting HDAC enzymes, HIP2101 increases acetylation of histones, leading to more open chromatin structure and altered transcription of genes involved in cell cycle arrest, differentiation, and apoptosis. This mechanism is particularly relevant in hematologic malignancies and solid tumors where epigenetic dysregulation drives disease progression.","oneSentence":"HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:34.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"},{"name":"Cutaneous T-cell lymphoma (CTCL)"}]},"trialDetails":[{"nctId":"NCT05024721","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-08-09","conditions":"Gastritis","enrollment":326},{"nctId":"NCT04967014","phase":"PHASE1","title":"Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-05-06","conditions":"Healthy Adult Volunteer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HIP2101","genericName":"HIP2101","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}